Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2B 〉Sofiva Genomics

Sofiva Genomics

Chat Now My Favorites
SOFIVA GENOMICS is an assembly of authoritative physicians and expert consultants in maternal-fetal medicine, cancer medicine, medical genetics, and clinical medicine. We aspire to act as both clinical physicians and research scientists and closely join fundamental medical research and clinical diagnosis together using translational medicine so as serve our mission and value in medical genetics.

Our research team endeavors in developing internationalized genetic test services for locals:
1. Reproductive Medicine Genetic Test
For the genetic diagnosis of rescue baby embryos before implantation, we offer preimplantation genetic diagnosis (PGD) and next generation sequencing-based preimplantation genetic screening (NGS-based PGS) so as to prevent hereditary disorders and improving artificial reproduction.
2. Prenatal Genetic Test
We were the first in the world to use PlGF & SFlt1 and hemodynamics to predict the occurrence of preeclampsia. We published an international academic paper and assisted a number of expecting mothers in successfully preventing the possible dangers that preeclampsia involves.
We were the first in Asia to incorporate gene chip (aCGH) techniques into prenatal diagnosis. We have accumulated over ten thousand cases and helped in the early diagnosis of chromosomal issues and microdeletion in fetuses.
Research on spinal muscular atrophy began early on. We also offer screening services to prevent recessive gene disorders from being passed on to the next generation.
Next generation sequencing (NGS), the most advanced in the world, involves non-invasive prenatal chromosome analysis and microdeletion screening. This test can be performed as early as the tenth week of gestation and requires only 10 c.c. of the mother's blood to understand the health status of the fetus. We also offer its innovative application to preimplantation genetic screening.
3. Neonatal Genetic Screening
We conduct research and offer screening tests for hereditary hearing loss, congenital central hypoventilation syndrome, and congenital cytomegalovirus infection to ensure the health of newborns.
4. Cancer Gene Screening Test
We develope variety of cancer gene screening tests, like MyGene Cancer One, MyGene Cancer Screening, MyGene Cancer Monitor, MyGene Hereditary Cancer, MyGene Women, MyGene Breast Cancer, MyGene Colon Cancer, MyGene Health etc.
5. Personalized Genetic Testing
We are actively developing a variety of personalized genetic tests for rare diseases, hereditary diseases, chronic diseases, and cardiovascular diseases as well as customized genetic testing services.
6. Rare Diseases Genetic Test
We provide genetic detection for more than 200 rare diseases. Please contact us if you required any other rare disease detection which is not listed in our service.

SOFIVA GENOMICS aims to be a guardian of health, starting with newborns. We have integrate conventional technologies, the novel NGS, and capture array to quickly examine necessary gene sequences and construct a platform for clinical genetic analysis and diagnosis. We possess international certification, which guarantees our technical quality, and offer internationalized genetic test services for locals with recognized experience and technology.

Our short-term and mid-term development goals are to maintain scientific research with clinical physicians and research institutes in Taiwan as well as close collaborations with international genetic testing and biomolecule manufacturers illumine and Roche with a view to building an even greater biological database and retaining our No. 1 status in technological power and innovation in Taiwan. Furthermore, we seek to provide services of greater quality to customers in addition to continued improvement and excellence. We aim to continue cooperating with Hong Kong, Thailand, Japan, Australia, Greece, Malaysia, and Indonesia and increase our test sample quantity. In addition to Shanghai in Mainland China, we will also branch out with collaborators to Beijing, Guangzhou, Zhenjiang, Jiangyin, and Chengdu.

For our long-term development goals, we expect to expand the applications of NGS and develop tests to obtain complete fetal chromosomes, microsegments, and single genes from samples of maternal blood as well as various personalized genetic tests that use samples of blood, saliva, and oral mucosa. We also hope to achieve more efficient searches and comparisons using the large biological database that we will accumulate so as to assist medical personnel in obtaining genetic information on drug metabolism and physiological effects and facilitate the identification of effective medication and treatments. Aside from providing international and professional services to people in Taiwan, we will also continue to expand our foreign market and spread the testing and medical power of Taiwan to Mainland China, India, and the ASEAN with technology transfer or the direct establishment of laboratories. We will also continue to develop a platform for rare diseases and bear the social responsibility we have given ourselves by assisting in the early diagnosis and treatment of rare diseases.

We offer a complete array of professional services, start from the clinical perspective, explore the actual demand in the market, and develop tests that customers really need. We incorporate new knowledge and technologies into routine examinations, provide highly convenient tests with low risk, really implement applications to clinical procedures, and offer accurate health plans or treatment guidelines so as to give everyone healthier lives.
  • Yi-Ning Su<br/>CEO & Managing Director

    Yi-Ning Su
    CEO & Managing Director

    * CEO of Sofiva Genomics
    * CEO of Dianthus MFM Center
    * Clinical Geneticist Specializing in Prenatal Diagnosis and Genetic Testing
  • Tzu-Hung Lin<br/>Medical Consultant

    Tzu-Hung Lin
    Medical Consultant

    * MD at Dianthus MFM Center
    * Chief consultant at Sofiva Genomics
    * Specializing in Perinatal Medicine, Genetic Medicine, High-risk Pregnancy
  • Chia-Chung Hung<br/>General Manager

    Chia-Chung Hung
    General Manager

    * General Manager of Sofiva Genomics
    * PhD in Biomedical Engineering and Medical Genomics and Proteomics
SOFIVA GENOMICS is an assembly of authoritative physicians and expert consultants in maternal-fetal medicine, cancer medicine, medical genetics, and clinical medicine. We aspire to act as both clinical physicians and research scientists and closely join fundamental medical research and clinical diagnosis together using translational medicine so as serve our mission and value in medical genetics.

Our research team endeavors in developing internationalized genetic test services for locals:
1. Reproductive Medicine Genetic Test
For the genetic diagnosis of rescue baby embryos before implantation, we offer preimplantation genetic diagnosis (PGD) and next generation sequencing-based preimplantation genetic screening (NGS-based PGS) so as to prevent hereditary disorders and improving artificial reproduction.
2. Prenatal Genetic Test
We were the first in the world to use PlGF & SFlt1 and hemodynamics to predict the occurrence of preeclampsia. We published an international academic paper and assisted a number of expecting mothers in successfully preventing the possible dangers that preeclampsia involves.
We were the first in Asia to incorporate gene chip (aCGH) techniques into prenatal diagnosis. We have accumulated over ten thousand cases and helped in the early diagnosis of chromosomal issues and microdeletion in fetuses.
Research on spinal muscular atrophy began early on. We also offer screening services to prevent recessive gene disorders from being passed on to the next generation.
Next generation sequencing (NGS), the most advanced in the world, involves non-invasive prenatal chromosome analysis and microdeletion screening. This test can be performed as early as the tenth week of gestation and requires only 10 c.c. of the mother's blood to understand the health status of the fetus. We also offer its innovative application to preimplantation genetic screening.
3. Neonatal Genetic Screening
We conduct research and offer screening tests for hereditary hearing loss, congenital central hypoventilation syndrome, and congenital cytomegalovirus infection to ensure the health of newborns.
4. Cancer Gene Screening Test
We develope variety of cancer gene screening tests, like MyGene Cancer One, MyGene Cancer Screening, MyGene Cancer Monitor, MyGene Hereditary Cancer, MyGene Women, MyGene Breast Cancer, MyGene Colon Cancer, MyGene Health etc.
5. Personalized Genetic Testing
We are actively developing a variety of personalized genetic tests for rare diseases, hereditary diseases, chronic diseases, and cardiovascular diseases as well as customized genetic testing services.
6. Rare Diseases Genetic Test
We provide genetic detection for more than 200 rare diseases. Please contact us if you required any other rare disease detection which is not listed in our service.

SOFIVA GENOMICS aims to be a guardian of health, starting with newborns. We have integrate conventional technologies, the novel NGS, and capture array to quickly examine necessary gene sequences and construct a platform for clinical genetic analysis and diagnosis. We possess international certification, which guarantees our technical quality, and offer internationalized genetic test services for locals with recognized experience and technology.

Our short-term and mid-term development goals are to maintain scientific research with clinical physicians and research institutes in Taiwan as well as close collaborations with international genetic testing and biomolecule manufacturers illumine and Roche with a view to building an even greater biological database and retaining our No. 1 status in technological power and innovation in Taiwan. Furthermore, we seek to provide services of greater quality to customers in addition to continued improvement and excellence. We aim to continue cooperating with Hong Kong, Thailand, Japan, Australia, Greece, Malaysia, and Indonesia and increase our test sample quantity. In addition to Shanghai in Mainland China, we will also branch out with collaborators to Beijing, Guangzhou, Zhenjiang, Jiangyin, and Chengdu.

For our long-term development goals, we expect to expand the applications of NGS and develop tests to obtain complete fetal chromosomes, microsegments, and single genes from samples of maternal blood as well as various personalized genetic tests that use samples of blood, saliva, and oral mucosa. We also hope to achieve more efficient searches and comparisons using the large biological database that we will accumulate so as to assist medical personnel in obtaining genetic information on drug metabolism and physiological effects and facilitate the identification of effective medication and treatments. Aside from providing international and professional services to people in Taiwan, we will also continue to expand our foreign market and spread the testing and medical power of Taiwan to Mainland China, India, and the ASEAN with technology transfer or the direct establishment of laboratories. We will also continue to develop a platform for rare diseases and bear the social responsibility we have given ourselves by assisting in the early diagnosis and treatment of rare diseases.

We offer a complete array of professional services, start from the clinical perspective, explore the actual demand in the market, and develop tests that customers really need. We incorporate new knowledge and technologies into routine examinations, provide highly convenient tests with low risk, really implement applications to clinical procedures, and offer accurate health plans or treatment guidelines so as to give everyone healthier lives.
  Video
  Video
Pipeline & Platform